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Compounds that inhibit signalling upstream of ERK
(extracellular-signal-regulated kinase) are promising anticancer
therapies, motivating research to deﬁne how this pathway
promotes cancers. In the present study, we show that human
capic´ uarepressesmRNAexpressionforPEA3(polyomaenhancer
activator 3) Ets transcription factors ETV1, ETV4 and ETV5
(ETV is Ets translocation variant), and this repression is relieved
by multisite controls of capic´ ua by ERK, p90
RSK (p90 ribosomal
S6 kinase) and 14-3-3 proteins. Speciﬁcally, 14-3-3 binds to
p90
RSK-phosphorylated Ser
173 of capic´ ua thereby modulating
DNA binding to its HMG (high-mobility group) box, whereas
ERK phosphorylations prevent binding of a C-terminal NLS
(nuclear localization sequence) to importin α4 (KPNA3). ETV1,
ETV4 and ETV5 mRNA levels in melanoma cells are elevated
by siRNA (small interfering RNA) knockdown of capic´ ua, and
decreased by inhibiting ERK and/or expressing a form of capic´ ua
that cannot bind to 14-3-3 proteins. Capic´ ua knockdown also
enhances cell migration. The ﬁndings of the present study give
further mechanistic insights into why ETV1 is highly expressed
in certain cancers, indicate that loss of capic´ ua can desensitize
cells to the effects of ERK pathway inhibitors, and highlight
interconnections among growth factor signalling, spinocerebellar
ataxias and cancers.
Key words: cancer, capic´ ua, Ets translocation variant 1 (ETV1),
14-3-3 protein, spinocerebellar ataxia type 1 (SCA1).
INTRODUCTION
Capic´ ua is a transcriptional repressor discovered in several
developmental contexts in Drosophila [1]. Signalling via
speciﬁc receptor tyrosine kinase/Ras/Raf/ERK (extracellular-
signal-regulated kinase) pathways relieves repression by capic´ ua
leading to the transcription of genes that specify differentiation
in wing veins, imaginal eye discs, head and tail [1−6], hence
the name capic´ ua meaning head-and-tail in Catalan. Lack of
capic´ ua enables Drosophila cells to grow without Ras function,
but does not compensate for growth defects due to mutations in
insulin/PKB (protein kinase B, Akt) signalling [6].
Mammalian capic´ ua (also known as CIC) is highly expressed
during development of the granule layers of the cerebellum [7],
and has been linked circumstantially to two disorders of neural
crest cell origin, namely SCA1 (spinocerebellar ataxia 1) and
Ewing’s family tumours [8−10].
SCA1isamotordisordercausedbyapolyglutamineexpansion
mutation of ataxin-1, with phosphorylation of Ser
776 potentiating
the disease [11,12]. Phosphorylated Ser
776 of ataxin-1 binds to
14-3-3 proteins, which are dimeric proteins that regulate many
cellular processes by docking on to speciﬁc phosphorylated
serine and threonine residues on their targets [13,14]. 14-3-3
binding to phosphorylated Ser
776 is proposed to regulate the
interactionsofataxin-1withtwoproteincomplexes,oneincluding
splicing factors and the other containing capic´ ua [10,15,16]. The
polyglutamine mutation of ataxin-1 that underlies SCA1 may
disturb the balance between the two complexes [10,15].
The suggestion of a connection between capic´ ua and cancer
comes from two cases of Ewing-like sarcoma that were found to
express transforming CIC−DUX4 (Double homeobox 4) fusion
proteins, comprising most of capic´ ua and part of the double
homeodomain protein DUX4 [8]. True Ewing-family tumours
more commonly arise from fusions of the EWS (Ewing sarcoma
protein) gene with genes encoding Ets transcription factors [17],
which raised the question of whether the CIC−DUX4 fusion
promotes the expression of Ets transcription factors. Indeed, the
HMG (high-mobility group) box of the CIC binds to a DNA
sequence within the promoters of genes encoding the PEA3
(polyomaenhanceractivator3)subfamilyEtstranscriptionfactors
[ETV1, ETV4 and ETV5 (ETV is Ets translocation variant),
also known as ER81, PEA3 and ERM respectively], whereas the
attached DUX4 portion enhances the transcription of ETV1 and
ETV5 [8]. One inference of these ﬁndings is that normal capic´ ua
might repress expression of ETV1, ETV4 and/or ETV5.
The three PEA3 Ets transcriptional activators have roles in
the development of many tissues and also in cancer progression.
For example, ETV1 targets include genes needed to synthesize
the neurotransmitter dopamine, as well as genes involved in
cell migration and cancer metastases [18]. In addition to
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EWS, chromosomal rearrangements involving gene fusions and
ampliﬁcations that lead to overexpression of ETV1, ETV4 and
ETV5havealsobeenidentiﬁedinbreastandprostatecancers,with
ETV1 in particular being linked to aggressive prostate tumours
and pinpointed as a driver mutation in melanomas [17,19−23].
Enhanced growth factor/ERK signalling has also been linked to
ETV1, ETV4 and ETV5 mRNA expression in developing tissues,
culturedmelanomacellsandgastrointestinalstromaltumoursthat
arepositiveforthereceptortyrosinekinaseKIT,butnounderlying
mechanisms have been described [24−27]. Phosphorylation of
the ETV1 protein by the ERK-activated p90
RSK (p90 ribosomal
S6 kinase) and/or MSK1 (mitogen- and stress-activated kinase 1)
have,however,beenfoundtoactivatethistranscriptionfactor[28].
Overall, these ﬁndings raise questions about potential
regulatory links between ERK signalling, capic´ ua and expression
of the PEA3 Ets transcription factors in human cells. Speciﬁcally,
does ERK signalling inhibit human capic´ ua by analogy with the
Drosophila protein? Does capic´ ua repress ETV1, ETV4 and/or
ETV5expression?Ifso,thesumofthesetwonegativeswouldbea
positiveeffectofERKsignallingontranscriptionofETV1,ETV4
and/or ETV5. We therefore began the present study by testing the
effectsofERK-activatinggrowthfactors,ERKpathwayinhibitors
and capic´ ua knockdown on the levels of ETV1, ETV4 and ETV5




Synthetic peptides were from Dr Graham Bloomberg (School of
Medical Sciences, University of Bristol, Bristol, U.K.). Mole-
cular-mass markers were from Bio-Rad. MG132 was from
Calbiochem. The ECL (enhanced chemiluminescence) kit
was from GE Healthcare. PD184352, PLX4720 and BI-
D1870 were from the DSTT (Division of Signal Tranduction
Therapy, University of Dundee, Dundee, Scotland, U.K.).
SDS/polyacrylamide precast gels and EGF (epidermal growth
factor) were from Invitrogen and PMA was from Sigma.
The pan-14-3-3 antibody (K-19), anti-GFP (green ﬂuorescent
protein) (sc-8334) and anti-CIC (goat; sc-67528) antibodies
were from Santa Cruz Biotechnology. Antibodies that recognize
phosphorylated Thr
202/Tyr
204 on ERK1/2 (#9101) and anti-ERK1/
2 (#9102) were from Cell Signaling Technology. The anti-
KPNA3 (importin α4/karyopherin α3) antibody is A301-626A
from Bethyl Laboratories, and recognizes an epitope between
residues 1 and 50 of human KPNA3 (GenBank® accession
numberNP_002258.2),whichisidenticalwithKPNA4.Theanti-
CIC (rabbit; ab61860) antibody was from Abcam.
Puriﬁed recombinant protein kinases generated in the DSTT
(Division of Signal Tranduction Therapy, University of Dundee,
Scotland, U.K.) were His−PKCα (protein kinase Cα; residues
1−672 of the human protein) expressed in insect cells
(constitutively active); His−PKCζ (protein kinase Cζ; residues
2−592 of the human protein) expressed in insect cells (con-
stitutivelyactive);His−RSK1(p90
RSK 1;residues1−735oftherat
protein) expressed in insect cells and activated by phospho-ERK2
and PDK1 (phosphoinositide-dependent kinase 1); His−RSK2
(p90
RSK 2; residues 2−740 of the rat protein) expressed in insect
cells and activated by phospho-ERK2 and PDK1.
Plasmids
Full-length human CIC (Q96RK0) was ampliﬁed from IMAGE
consortium EST (expressed sequence tag) 100014433 and cloned
intoaderivativeofpcDNA5FRT/TO(Invitrogen)thatcontainsthe
coding sequence for GFP upstream of the multiple cloning site, to
expressN-terminallytaggedGFP−CIC.C-terminaltruncationsof
CICweregeneratedfromthisplasmidbyinsertingastopcodonat
the appropriate position by mutagenesis. N-terminal truncations
were made by re-amplifying the appropriate fragments of CIC
and cloning into the same vector. Point mutations of CIC were
introduced using KOD Hot Start DNA Polymerase (Novagen).
GST-tagged CIC fragments were generated by re-amplifying the
appropriate fragment from existing plasmids and cloning into
the pGEX6P vector (GE Healthcare).
Full-length human KPNA3 (O00505) was ampliﬁed from
humanbraintotalRNA(Stratagene)andclonedintoaderivativeof
pcDNA5 FRT/TO (Invitrogen) that contains the coding sequence
for the HA (haemagglutinin) tag upstream of the multiple cloning
site.
All plasmids were sequence-veriﬁed and plasmid transfections





Cell stimulations, lysis and isolation of GFP-tagged proteins
Human HEK-293 cells cultured on 10-cm-diameter dishes in
DMEM (Dulbecco’s modiﬁed Eagle’s medium) containing 10%
(v/v) FBS (fetal bovine serum) were used untransfected, or
24−36 h after transfection with the plasmids indicated. Cells
were serum-starved for a further 4−8 h (unstimulated), then
stimulated with 100 ng/ml EGF for 15 min and 100 ng/ml
PMA for 30 min. Where indicated, cells were incubated with
PD184352 (2 μM for 1 h) and BI-D1870 (10 μM for 30 min)
prior to stimulation with EGF and PMA. After stimulations,
the medium was aspirated and cells lysed in 0.3 ml of
ice-cold lysis buffer comprising 25 mM Tris/HCl (pH 7.5),
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 50 mM NaF,
5 mM sodium pyrophosphate, 1 mM sodium orthovanadate,
1 mM benzamidine, 0.2 mM PMSF, 0.1% 2-mercaptoethanol,
1 μM microcystin-LR, 0.27 M sucrose and one mini Complete
TM
proteinase inhibitor cocktail tablet (Roche) per 10 ml of lysis
buffer. Lysates were clariﬁed by centrifugation (15000 g for
2 min), snap-frozen and stored at −80◦C. Protein concentrations
weredeterminedwithCoomassieProteinAssayReagent(Thermo
Scientiﬁc).
To isolate GFP-tagged proteins, 5 μl of GFP–Trap®-agarose
(http://www.chromotek.com) was mixed with 1−3m go fl y s a t e
on an orbital shaker at 4◦C for 1 h, and washed by centrifugation
(15000 g for 30 s) and resuspension, twice in 1 ml of TBS [Tri-
buffered saline; 25 mM Tris/HCl (pH 7.5) and 150 mM NaCl],
and twice in 1 ml of TBS containing Tween 20 (0.1% by vol.).
Proteins were extracted into 20−40 μl of SDS sample buffer
(Invitrogen) containing 1% 2-mercaptoethanol.
Western blots and 14-3-3 overlays
Membranes were incubated in 50 mM Tris/HCl (pH 7.5),
0.15 M NaCl and 0.2% Tween 20 containing 5% (w/v)
dried skimmed milk powder (Marvel) and immunoblotted at
4◦C for 16 h [or room temperature (22◦C) for 1 h for anti-
GFP and anti-HA antibodies] using the antibodies indicated
at 1 μg/ml. Detection was performed using HRP (horseradish
peroxidase)-conjugated secondary antibodies (Promega) and
ECL® (Amersham Biosciences) for Western blots of endogenous
proteins, except phospho- and total ERK1/2 for which secondary
antibodies were labelled with IRDye and detected by Li-Cor IR
imaging. 14-3-3 Far-Western assays are similar to Western blots,
but use DIG (digoxygenin)-labelled 14-3-3 in place of primary
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antibody to test the ability of phosphorylated proteins on the
membranes to bind directly to 14-3-3 [13].
In vitro kinase assay
Phosphorylation reactions were performed at 30◦C in a total
volume of 20 μl. The protein kinase reaction buffer contained
50 mM Tris/HCl (pH 8.0), 1 mM EGTA, 10 mM EDTA, 100 mM
MgAc and 1 mM ATP with or without 50 m-units/μl of protein
kinases(where1 unitis1 nmolofphosphateincorporatedpermin
at30◦Cintostandardsubstratepeptides).Reactionswerestopped
with SDS sample buffer (Invitrogen).
Identiﬁcation of proteins and phosphorylated residues by mass
spectrometric analyses
Protein identiﬁcation by tryptic mass ﬁngerprinting analysis
of selected protein gel bands was performed by LC-MS/MS
(liquid chromatography tandem MS) using a linear ion trap-
orbitraphybridmassspectrometer(LTQ-Orbitrap,ThermoFisher
Scientiﬁc)equippedwithananoelectrosprayionsource(Thermo)
and coupled to a Dionex Ultimate 3000 nano-HPLC system.
Peptides were typically injected into a PepMap 100 reverse-
phase C18 3 μm column (Dionex) with a ﬂow of 300 nl/min and
eluted with a 40 min linear gradient of 95% s o l v e n tA( 2 %
acetonitrile and 0.1% formic acid in water) to 50% solvent
B( 9 0 % acetonitrile and 0.08% formic acid in water). The
instrument was operated with the ‘lock mass’ option to improve
the mass accuracy of precursor ions and data were acquired
in the data-dependent mode, automatically switching between
MS and MS/MS acquisition. Full scan spectra (m/z 300−1800)
were acquired in the orbitrap with resolution R=60000 at m/z
400 (after accumulation to a target value of 500000). The ﬁve
most intense ions, above a speciﬁed minimum signal threshold of
50000, based upon a low-resolution (R=15000) preview of the
survey scan, were fragmented by collision-induced dissociation
and recorded in the linear ion trap (target value of 10000).
Phosphopeptides were identiﬁed by LC-MS and MS/MS
on an Applied Biosystems 4000 QTrap coupled to a
Dionex/LC Packings Famos/Switchos/Ultimate HPLC. The mass
spectrometer was set to use a precursor ion scan of m/z −79
in negative-ion mode followed by an ion-trap high-resolution
scan (enhanced resolution scan) and a high-sensitivity MS/MS
scan (enhanced product ion scan) in positive mode. Peptides were
typically injected on to a PepMap 100 reverse-phase C18 3 μm
column with a ﬂow of 300 nl/min and eluted with a 40 min linear
gradient of 95% solvent A (2% acetonitrile and 0.1% formic
acid in water) to 50% solvent B (90% acetonitrile and 0.08%
formicacidinwater).AHarvardsyringepumpwasusedtodeliver
propan-2-ol at a ﬂow of 100 nl/min with mixing occurring at a
T-junction after the LC and prior to the MS [29].
Melanoma cell culture and cell migration
The human melanoma cell lines were kindly provided by Dr
RichardMarais(TheInstituteofCancerResearch,London,U.K.).
SKMEL13 melanoma cells were maintained in RPMI containing
10% FBS, and SBCL2 and PWMK cells in DMEM containing
10% FBS in a humidiﬁed incubator with 5% CO2 at 37◦C. The
ability of cells to migrate was tested in a growth-factor-reduced
Matrigel
TM invasion chamber (BD Biosciences).
Immunoﬂuorescence and microscopy
Cells grown on coverslips were ﬁxed in −20◦C methanol,
permeabilized with 0.2% Triton X-100, rinsed with PBS,
stainedwithDAPI(4
 ,6-diamidino-2-phenylindole)andmounted.
The slides were taken on a Zeiss LSM700 microscope using
an alphaPlan-Apochromat ×100 NA (numerical aperture) 1.46
objective and digital images were analysed in Adobe Photoshop.
Quantitative RT (reverse transcription)−PCR analysis
Melanoma cells (250000 per well) were seeded in six-well
culture plates and total RNA was isolated using the RNeasy
minikit (Qiagen) and treated with RNase-Free DNase (Qiagen).
RNA (1 μg) was converted into cDNA using Quanta Bio-
sciences qScript
TM cDNA SuperMix (95048−500) using the
following primer sequences: CIC (Forward) 5
 -GGTAC-
TGGCAAGAAGGTGAAGG-3
  and CIC (Reverse) 5
 -AC-
TCAGGCAACTCAGCAAAGC-3
 ; ETV1 (Forward) 5
 -CCC-
TCCATCGCAGTCCATACC-3
  and ETV1 (Reverse) 5
 -CT-
TGGCATCGTCGGCAAAGG-3
 ; ETV4 (Forward) 5
 -CAGGC-
GGAGGTTGAAGAAAGG-3
  and ETV4 (Reverse) 5
 -AAG-
GGCAGAAGAAAGGCAAAGG -3
 ; ETV5 (Forward) 5
 -GG-
GAAATCTCGATCAGAGGACTG-3
  and ETV5 (Reverse)
5
 -GGAGCATGAAGCACCAAGTT-3
 ;B 2 M( β2 microglo-
buluin) (Forward) 5
 - TGCCGTGTGAACCATGTG -3




(glyceraldehyde-3-phosphate dehydrogenase) (Forward) 5
 -
CAATGACCCCTTCATTGACC-3
  and GAPDH (Reverse) 5
 -
GACAAGCTTCCCGTTCTCAG-3
 ;a n dβ-actin (Forward) 5
 -
TCTACAATGAGCTGCGTGTG-3
  and β-actin (Reverse) 5
 -
TAGATGGGCACAGTGTGGGT-3
 . PCR cycling steps for the
Bio-Rad iCycler iQ® of PCR products were 30 s at 95◦Cf o r
initial denaturation, 30 s at 60◦C for annealing, and 30 s at 72◦C
for extension. All assays were performed with the comparative
threshold cycle (Ct) method, the average of three analyses for
each gene was calculated and data were normalized to an internal
standard gene of B2M.
siRNAs (small interfering RNAs)
ON-TARGET plus SMARTpool siRNA for human capic´ ua
consisting of four individual siRNAs (GCUUAGUGUA-
UUCGGACAA, CGGCGCAAGAGACCCGAAA, GAGAAGC-
CGCAAUGAGCGA and CGAGUGAUGAGGAGCGCAU) was
from Dharmacon. siRNA oligonucleotides were transfected
into cells at 40−60% conﬂuency using Lipofectamine
TM 2000
(Invitrogen).
EMSAs (electrophoretic mobility-shift assays)
Biotin-labelled and unlabelled forms of the following
oligonucleotide and complementary sequence were synthes-
ized (Invitrogen): biotin−GTCGCGTTTTTTATGAATGAA-
AAACGTCCTTACATTCATT [octameric CRE (CIC-responsive
element) in the ETV4 and ETV5 promoters [8] is shown in bold
type]. (The CRE in the ETV1 promoter has a G in place of the
A where underlined [8]). The LightShift® Chemiluminescent
EMSA Kit (Pierce) was used for the EMSA assays. The
binding reactions (30 min at room temperature in 20 μl) were
carried out in the presence of 2.5 ng of poly(dI-dC) in 1×
binding buffer using 100 pmol of biotin-labelled duplex probe
and, where indicated, a 20-fold molar excess of unlabelled
probe. Reactions were stopped by adding 5× loading buffer.
DNA−protein complexes were separated on 5% Novex DNA
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Figure 1 Effect of EGF, PD184352 and capic´ ua knockdown on expression of ETV1, ETV4 and ETV5 mRNAs in BRAF(V600E) SKMEL13 and/or wild-type PMWK
melanoma cells
(A) qRT-PCR of ETV1, ETV4 and ETV5 mRNA from PMWK cells stimulated with EGF (100ng/ml) for the number of hours indicated (black bars), IGF1 (50ng/ml) for 24h (black bars) and with no
stimulus(greybars).GeneexpressionisnormalizedrelativetotheinternalcontrolgeneB2M,assigningavalueof1.0forthezerotimepointwithnostimulus.Valuesaremeans+ −S.D.(fourdifferent
sets of analyses for each data point). (B) Western blot of whole-cell lysate of PMWK cells stimulated with EGF for the times indicated, and immunoblotted with the antibodies indicated to monitor the
phosphorylation status of ERK. (C) The effect of the ERK pathway inhibitor PD184352 (2 μM, [30]), BRAF(V600E) inhibitor PLX4720 (10 μM, [31]) and p90RSK inhibitor BI-D1870 (10 μM, [32])
on expression of ETV1, ETV4 and ETV5 in SKMEL13 cells at the times indicated in hours (black bars). Data for cells with no inhibitor are shown as grey bars. Gene expression is normalized to the
internal control gene B2M, assigning a value of 1.0 for the zero time point with no inhibitor. Values are the means+ −S.D. (four different sets of analyses for each data point).
retardation gels (Invitrogen). The complexes were blotted on to a
positivelychargedBiodynenylonmembrane(ThermoScientiﬁc),
the membrane reacted with a Spectrolinker XL-1500 UV cross-




ETV1, ETV4 and ETV5 expression is blocked by inhibitors of the
ERK cascade and enhanced by EGF stimulation and siRNA
knockdown of capic´ ua in melanoma cells
In a wild-type melanoma cell line PMWK, the level of ETV4
and ETV5, but not ETV1, mRNAs was increased in response to
EGF stimulation (Figure 1A), which activates prolonged ERK
signalling in these cells (Figure 1B), whereas IGF1 (insulin-like
growth factor 1) did not affect either ERK phosphorylation or
expression of the PEA3 Ets transcription factors (Figure 1A,
and results not shown). SKMEL13 melanoma cells carry the
BRAF(V600E) mutation rendering the ERK signalling pathway
constitutively active. In SKMEL13 cells, the mRNA levels for
ETV1, ETV4 and ETV5 were markedly decreased by the ERK
pathway inhibitor PD184352 [30] and BRAF(V600E) inhibitor
PLX4720 [31], and partially decreased by the p90
RSK inhibitor
BI-D1870 [32] (Figure 1C). p90
RSK is activated downstream of
ERKinthemelanomaandHEK-293cellsusedinthepresentstudy
(resultsnotshown).Similarly,ETV1,ETV4andETV5expression
was inhibited by PD184352 and, to a lesser extent by BI-D1870,
inSbcl2cells,whicharemutantforN-Ras(SupplementaryFigure
S1 at http://www.BiochemJ.org/bj/433/bj4330515add.htm).
Down-regulating capic´ ua expression in SKMEL13 melanoma
cells (Figure 2A) increased mRNA levels for ETV1, ETV4 and
ETV5 (Figure 2B). Furthermore, the knockdown of capic´ ua
lessened the ability of PD184352 to inhibit the expression
of ETV1 and ETV5 mRNAs (Figure 2C). Taken together,
these data indicate that capic´ ua suppresses and ERK activity
supports the expression of ETV1, ETV4 and ETV5 mRNAs.
c   The Authors Journal compilation c   2011 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Growth factors regulate capic´ ua and ETV1 519
Figure 2 Effect of capic´ ua knockdown on expression of ETV1, ETV4 and ETV5 mRNAs in BRAF(V600E) SKMEL13 melanoma cells
(A) The expression of CIC mRNA in SKMEL13 cells treated with CIC siRNAs (siCIC, black bars) compared with mock-transfected controls (grey bars). Values are means+ −S.D. (four different sets
of analyses for each data point). (B) The expression of ETV1, ETV4 and ETV5 mRNA in the same SKMEL13 cells treated with CIC siRNAs that are shown in (A), with data for siRNA-treated cells in
black and mock-transfected controls in grey. Values are means+ −S.D. (four different sets of analysis for each data point). (C) The effect of CIC knockdown followed by exposure to 2 μM PD184352
on ETV1, ETV4 and ETV5 mRNA expression in SKMEL13 cells. Black bars represent data for cells treated with siCIC (siRNA for CIC) and PD184352 for the times indicated, whereas grey bars are for
mock-transfected cells treated with PD184352. Values are means+ −S.D. (four different sets of analyses for each data point). (D) Cells at 30−40% conﬂuency in six-well plates were transfected with
siCIC,non-targetingsiRNAthatdoesnottargetanyknowngenesasacontrol(siNT)andmocktransfection.After24h,cellswereserum-deprivedfor2 h,detachedwithcelldissociationbuffer(Gibco),
counted, and added in migration buffer (750 μl of DMEM containing 1% BSA) to the upper chambers of a growth factor-reduced MatrigelTM invasion device (BD Biosciences) with chemoattractant
(DMEM containing 10% FBS) in the lower wells. The cells that did not migrate were removed from the upper face of the ﬁlters using cotton swabs, and cells that had migrated to the lower face of
the ﬁlters were ﬁxed with Reastain Quick-Diff kit (Reagena). Images (×10) were captured (examples are shown in Supplementary Figure S2 at http://www.BiochemJ.org/bj/433/bj4330515add.htm),
migrated cells counted in ﬁve randomﬁelds, and the histogram showsthe number of cells that migrated to the lower face of the ﬁlters, presented as means+ −S.D. for the two experimentalconditions
(that is experiments starting with 2.5×105 and 1×105 cells respectively).
Furthermore, when Sbcl2 melanoma cells were allowed to
migrate in a Matrigel
TM invasion chamber after knockdown of
capic´ ua, the knockdown cells displayed a 40−50% increase
in migration compared with the control cells (Figure 2D and
Supplementary Figure S2 at http://www.BiochemJ.org/bj/433/
bj4330515add.htm).
EGF and phorbol ester inhibit binding of KPNA3 (importin α4) and
promote binding of 14-3-3 to capic´ ua
We next explored whether capic´ ua is a target of regulation
by ERK signalling. HEK-293 cells expressing GFP−capic´ ua
were stimulated with EGF and PMA to activate ERK, and the
GFP−capic´ ua protein was immunoprecipitated from lysates. An
∼60 kDaproteinwasco-immunoprecipitatedwithGFP−capicua
from unstimulated cells, but not EGF- and PMA-stimulated cells,
and was identiﬁed as importin α4/karyopherin α3 (KPNA3)
by mass spectrometric analysis of tryptic peptides and Western
blotting (Figure 3A). Although inhibiting p90
RSK with BI-D1870
had no effect on the capic´ ua−KPNA3 interaction, inhibiting
upstream ERK signalling with PD184352 (Figures 3A and 3B)
and UO126 (results not shown) restored the binding of capic´ ua to
KPNA3inEGF-stimulatedcells(Figures3Aand3B)andphorbol
ester-stimulated cells (results not shown).
GFP−capic´ ua also interacted with 14-3-3 proteins, visualized
as two Coomassie-Blue-stained bands of which the upper
contained14-3-3εandthelowercomprised14-3-3θ,γ,α/β,ηand
δ/ζ (Figure 3A). 14-3-3σ is absent from these cells and was not
detected.IncontrastwithKPNA3,thecapic´ ua−14-3-3interaction
was promoted by EGF and PMA, and was prevented when p90
RSK
was inhibited directly with BI-D1870 and when upstream ERK
signalling was blocked with PD184352 (Figures 3A and 3B) and
UO126 (results not shown). The binding of capic´ ua to 14-3-3 was
alsopromotedbyIGF1,althoughtoalesserextentthanwithEGF,
and the response to IGF1 was blocked by PI3K (phosphoinositide
3-kinase) inhibitors (results not shown).
Tryptic digests of the extracted GFP−capic´ ua from EGF-
stimulated cells were analysed by precursor ion scanning
and MS/MS, revealing the presence of several phospho-
peptides (Supplementary Figure S3 at http://www.BiochemJ.
org/bj/433/bj4330515add.htm). Taken together with previous
phosphorylation site data [13] (http://www.phosphosite.org),
several phosphorylated residues within RXX(pS) motifs that are
potential p90
RSK and 14-3-3-binding sites were identiﬁed near
the HMG box, such as phosphorylated Ser
173 (Supplementary
c   The Authors Journal compilation c   2011 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.520 K. Dissanayake and others
Figure 3 Identiﬁcation of regulated phosphorylated sites on GFP−capic´ ua and its regulated interactions with KPNA3 and 14-3-3
(A) GFP−capic´ ua (CIC) and GFP (control) proteins were isolated from lysates of transfected cells using GFP−Trap® (an immobilized single-chain antibody) coupled to agarose. Cells were
stimulatedwithEGF(100ng/mlfor30min)andPMA(100ng/mlfor30min)withorwithoutpre-incubationwiththep90RSK inhibitorBI-D1870(10μMfor30min).Capturedproteinsweresubjected
to SDS/PAGE, gels were stained with colloidal Coomassie Blue, and proteins and phosphorylated sites were identiﬁed by MS as described in the Materials and methods section and Supplementary
FigureS3(athttp://www.BiochemJ.org/bj/433/bj4330515add.htm).ArrowspointtotheproteinsidentiﬁedasGFP−capic´ ua(GFP−CIC),14-3-3sandKPNA3.ThemolecularmassinkDaisindicated
on the left-hand side. (B) Effects of inhibitors of the ERK pathway and p90RSK on the EGF-regulated binding of KPNA3 and 14-3-3 to GFP−capic´ ua. HEK-293 cells were transfected to express
GFP−CIC (full-length, WT) and GFP−CIC-(1−450), and stimulated or not with EGF+ −PD184352 (2 μM inhibitor for 60 min) and+ −BI-D1870 (10 μM inhibitor for 30min). EGF was used at
100ng/mlfor30min.Lysates(2.5mg)weresubjecttoGFP−Trap® immunoprecipitation,followedbyimmunoblottingwiththeantibodiesindicated.Inaddition,theabilityoftheGFP−CIC-(1−450)
to bind directly to 14-3-3 was tested with a 14-3-3 Far-Western assay. IB, immunoblot.
Figure S3). In contrast, the C-terminal region of capic´ ua is
phosphorylated mainly on (pS/T)P motifs, which are potential
ERK sites, but not the type of motif generally associated with
binding to 14-3-3 proteins (Supplementary Figure S3).
ERK phosphorylation of capic´ ua blocks binding of a C-terminal NLS
(nuclear localization sequences) to KPNA3
The importin-α proteins bind to NLS in cargo proteins
that are then carried into the nucleus. A cluster of basic
residues (K
1411RKMRR
1416) in the C-terminal region of capic´ ua
conformed to a potential monopartite NLS (http://cubic.
bioc.columbia.edu/db/NLSdb/). Consistent with KRKMRR
binding to KPNA3, GFP−capic´ ua-(1−450) did not bind
to KPNA3 (Figure 3B), but GFP−capic´ ua-(451-end) did bind to
KPNA3 in lysates of unstimulated cells (results not shown).
Also, KPNA3 binding was lost when KRKMRR was changed
to KAAMRR in full-length GFP−capic´ ua (Figure 4A), and
when the C-terminal region containing this sequence was
deleted in GFP−capic´ ua-(1−1320) and GFP−capic´ ua-(1−1400)
(Figure 4B). The interaction between capic´ ua and KPNA3 in cell
lysates was also blocked by competition with a synthetic peptide
containing the canonical NLS sequence from Simian virus 40
large T-antigen, but not a mutant version [33] (Figure 4C).
The results in Figures 3(A) and 3(B) indicated that phospho-
rylation of capic´ ua and/or KPNA3 by ERK prevents the
interaction between these two proteins. To determine which is
the relevant ERK target, GFP−capic´ ua and HA−KPNA3 were
expressed separately in HEK-293 cells that were stimulated
or not with EGF+ −PD184352. When the various cell lysates
were mixed and GFP−capic´ ua extracted, only GFP−capic´ ua
from unstimulated and PD184352-treated cells was bound to
HA−KPNA3 (Figure 4D). In contrast, HA−KPNA3 could bind
to GFP−capic´ ua irrespective of whether the HA−KPNA3-
expressing cells had been stimulated with EGF (Figure 4D). This
means that ERK phosphorylation of capic´ ua blocks its interaction
with KPNA3.
When the 11 (pS/T)P sites identiﬁed on capic´ ua were mutated,
only alanine mutations of Ser
1382 and Ser
1409, which are closest to
theNLS,preventedtheEGF-inducedlossofbindingofcapic´ uato
KPNA3 (Figure 4E and results not shown). These results suggest
that ERK phosphorylation of Ser
1382 and Ser
1409 masks the NLS
and prevents its binding to KPNA3.
We hypothesized that disruption of the NLS, and EGF-
stimulated dissociation of capic´ ua from KPNA3, would prevent
capic´ ua from entering the nucleus. In contrast, however, full-
length GFP−capic´ ua was nuclear under all conditions tested,
even when the NLS was mutated (results not shown). However,
the C-terminal part of GFP−capic´ ua (residue 451 to the end)
required the intact NLS for its nuclear localization (Figure 4F
and Supplementary Figure S4 at http://www.BiochemJ.org/bj/
433/bj4330515add.htm). These data indicate that, although the
NLS−importin interaction has the potential to direct localization,
capic´ ua also has other mechanisms for getting into the nucleus.
Indeed, the N-terminal half of the protein was also nuclear, even
though it does not bind to KPNA3, indicating that this part of the
protein also speciﬁes nuclear targeting (Supplementary Figure
S4).
14-3-3 binds to the evolutionarily conserved p90RSK-
phosphorylated Ser173, adjacent to the HMG box of capic´ ua
Both full-length protein and truncated GFP−capic´ ua (residues
1−450) bound to 14-3-3 proteins in response to EGF and PMA
(Figures 3A, 3B and 5A, and results not shown). However,
GFP−capic´ ua(S173A) showed only a trace of EGF- and PMA-
stimulated binding to 14-3-3 proteins (Figure 5A), implicating
phospho-Ser
173 [KRRTQ(pS
173)LS] in 14-3-3 binding. Consistent
with the cellular analyses, GST−capic´ ua-(1−450) that was
phosphorylated in vitro on Ser
173 and other residues by p90
RSK
could bind to 14-3-3 proteins (Figure 5B), whereas S173A-
substituted protein could not (results not shown).
Ser
173 is conserved in metazoan forms of capic´ ua
(Supplementary Figure S5 at http://www.BiochemJ.org/bj/
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Figure 4 Mechanism of regulated binding of an NLS in GFP−capic´ ua to KPNA3
(A) HEK-293 cells were transfected to express GFP−capic´ ua (GFP−CIC) and GFP−capic´ ua with a double R1412A and K1413A substitution in the putative NLS [GFP−CIC (NLS*)], and stimulated
or not with EGF+ −PD184352. Lysates were subjected to GFP−Trap® immunoprecipitation, and immunoprecipitates and whole-cell lysates were immunoblotted with the antibodies indicated.
(B) HEK-293 cells were transfected to express the indicated GFP−capic´ ua proteins and stimulated or not with EGF. Cell lysates and GFP−Trap® immunoprecipitates were analysed with the
antibodies indicated. (C) HEK-293 cells were transfected to express GFP−capic´ ua and cell lysates were incubated with the indicated concentrations of synthetic wild-type (CASPKKKRKV-OH) or
mutant (CASPKTKRKV-OH) simian-virus-40 large T-antigen NLS peptides for 30min at 4◦C followed by GFP−Trap® immunoprecipitation and analysis by immunoblotting. (D) GFP−capic´ ua and
HA−KPNA3 were expressed separately in HEK-293 cells that were stimulated or not with EGF+ −PD184352. Different combinations of the lysates were mixed as indicated, and GFP−capic´ ua was
immunoprecipitatedfromthemixturesandimmunoblottedwiththeantibodiesindicated.(E)HEK-293cellsweretransfectedtoexpresswild-typeandmutatedformsofGFP−capic´ uaasindicatedand
stimulated or not with EGF+ −PD184352 followed by GFP−Trap® immunoprecipitation. Immunoprecitated proteins were analysed by Western blotting using anti-GFP and anti-KPNA3 antibodies.
(F) DAPI staining and GFP immunoﬂuorescence of HEK-293 cells transfected with the indicated GFP−capic´ ua constructs. Scale bar=10 μm. IB, immunoblot.
433/bj4330515add.htm). When expressed in human cells,
Drosophila capic´ ua interacted with 14-3-3 in response to EGF
and PMA, and this interaction required Ser
461, corresponding to
Ser
173 in the human protein (Figure 5C). Thus 14-3-3 binding
to p90
RSK-phosphorylated Drosophila capic´ ua may help explain
how its repressor activity is relieved by ERK signalling in ﬂies
[1].
14-3-3 proteins are dimeric and often bind to two
phosphorylated sites on their targets [14], and we therefore
searched for a second 14-3-3-binding site on human capic´ ua.
Singleserine-to-alaninesubstitutionofotherphosphorylatedsites
identiﬁed between residues 1 and 450 (Supplementary Figure
S3) had no obvious effect on 14-3-3 binding. A truncated
GFP−capic´ ua-(1−370) with S173A did not show even trace
binding to 14-3-3 proteins, however (Figure 5D), and we
tentatively conclude that phospho-Ser
431 [SQRAA(pS
431)ED] or
a nearby residue provides a second low-afﬁnity binding site for a
14-3-3 dimer.
This proposed conﬁguration of a 14-3-3 dimer straddling
phosphorylated Ser
173 and possibly phospho-Ser
431 on either side
of the DNA-binding HMG box (residues 200−268) suggests that
the 14-3-3 protein might directly affect the binding of capic´ ua to
DNA. Consistent with this hypothesis, we found that capic´ ua
bound to double-stranded DNA containing the minimal CRE
(5
 -TGAATGAA-3
 ), which was previously identiﬁed to bind
to capic´ ua [8], and addition of exogenous 14-3-3 to p90
RSK-
phosphorylated capic´ ua decreased the capic´ ua interaction with
DNA (Figure 5E). 14-3-3 had no effect on DNA binding of
unphosphorylated capic´ ua (Figure 5E).
Expression of ETV1, ETV4 and ETV5 in melanoma cells is inhibited
by a form of capic´ ua that cannot bind to 14-3-3
Endogenous capic´ ua also binds to 14-3-3 in lysates of melanoma
cells containing constitutively active ERK, and this interaction
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Figure 5 Identiﬁcation of the p90RSK-phosphorylated and 14-3-3-binding residues on human and Drosophila capic´ ua proteins
(A) HEK-293 cells were transfected with the indicated GFP−capic´ ua constructs and stimulated or not with EGF+ −BI-D1870. Lysates were subject to GFP−Trap® immunoprecipitation, and
immunoprecipitates and lysates were immunoblotted with the indicated antibodies. The ability of GFP−capic´ ua proteins to bind to 14-3-3 in vitro was assessed by a 14-3-3 Far Western assay. (B)
Puriﬁed recombinant constitutively active forms of PKCα, PKCζ, p90RSK1 and p90RSK2 were used for in vitro phosphorylation of GST−capic´ ua (CIC)-(1−450). The reactions were performed
with or without kinase in the presence of Mg-ATP. A 14-3-3 Far Western assay was used to assess the ability of phosphorylated protein to bind to 14-3-3. (C) Lysates from HEK-293 cells transfected
to express the indicated Drosophila capic´ ua proteins, and stimulated or not with EGF+ −BI-D1870 and PMA+ −BI-D1870 were subjected to GFP pulldown assay followed by immunoblotting with
the antibodies indicated. Direct binding to 14-3-3 was detected in a 14-3-3 Far Western assay. (D) HEK-293 cells were transfected to express the indicated GFP−capic´ ua proteins and stimulated or
not with EGF+ −BI-D1870 and subjected to GFP−Trap® immunoprecipitation. Immunoprecipitates were immunoblotted with the indicated antibodies. 14-3-3 interaction was detected in 14-3-3 Far
Western assay. (E) EMSAs were performed using biotin-labelled DNA probe containing CRE. Where indicated, unlabelled DNA was also included. DNA was incubated with GST−capic´ ua-(1−450)
(1 μM) that was phosphorylated in vitro with p90RSK (right-hand panel) or not (left-hand panel), and used in the presence and absence of 5 μM 14-3-3 dimer. The upper arrow shows the
GST−capic´ ua−DNA complex. Lower bands indicate that the added 14-3-3 has some sequence-non-speciﬁc afﬁnity for DNA. IB, immunoblot; WT, wild-type.
is prevented by PD184352 (Figure 6A), whereas in wild-type
melanoma cells the capic´ ua−14-3-3 interaction depends on EGF
(Figure 6B). This ﬁnding suggested that the p90
RSK- and 14-3-
3-mediated regulation of capic´ ua might contribute to the ERK-
dependent expression of ETV1, ETV4 and ETV5 (Figure 1A),
and we tested this hypothesis. Overexpressing capic´ ua-(90−450)
had no obvious effect on mRNA levels for these Ets transcription
factors. However, their expression, particularly for ETV5, was
decreased by expressing capic´ ua-(90−450) with Ser
173 replaced
by alanine, and more-so by a form of capic´ ua lacking all ﬁve
of the phosphorylated sites identiﬁed in the N-terminal half
of the protein (Figures 6C and 6D). These data are consistent
with the hypotheses that capic´ ua contributes to the repression of
transcription of ETV1, ETV4 and ETV5, and p90
RSK-mediated
binding of 14-3-3 to capic´ ua inhibits its repression of these Ets
transcription factors.
DISCUSSION
The ERK cascade regulates cellular proliferation, differentiation
and survival, and is commonly activated in human cancers where
it is associated with tumour aggression and metastases. In the
present paper, we provide mechanistic and functional evidence
of a regulatory pathway linking ERK signalling via inhibition
of the transcriptional repressor capic´ ua to expression of the
PEA3 Ets transcription factors that promote the transcription of
pro-metastatic genes. Our ﬁndings could therefore explain why
mRNA levels of ETV1 in particular are often elevated in breast,
prostate, melanoma, gastrointestinal and other tumours, even
when ETV1 overexpression is not driven by gene ampliﬁcation
or fusion to another gene [17,19,20,22−24,27]. In particular,
our data are consistent with the identiﬁcation of ETV1 and
ETV5 in screens for mRNAs whose expression was decreased
by BRAF(V600E)/MEK [MAPK (mitogen-activated protein
kinase)/ERK kinase] inhibitors in melanoma cells [25,26]. It
is also tempting to speculate that the mechanism that we
describe in the present paper could conceivably underpin the
KIT receptor tyrosine kinase/ERK-driven expression of ETV1
in GISTs (gastrointestinal stromal tumours) [27]. High ETV1
expression was found to support growth of GIST cell lines,
whether they contained KIT that is sensitive or resistant to
imatinib (Gleevec) [27]. Placing capic´ ua and ETV1/ETV4/ETV5
in a transcriptional axis downstream of ERK therefore raises the
pressing question of whether loss or inactivation of capic´ ua,
and hence expression of ETV1, could desensitize tumours to
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Figure 6 Effect of overexpressing capic´ ua that cannot bind to 14-3-3 on regulation of ETV1, ETV4 and ETV5 mRNA expression in BRAF(V600E) SKMEL13
melanoma cells
(A) Western blot of endogenous capic´ ua isolated by its binding to 14-3-3−Sepharose in lysates of BRAF(V600E) SKMEL13 cells, and also the indicated cells with constitutively active RAS proteins.
Cells were treated with 2 μM PD184352 for 60min where indicated, and the phosphorylation status of ERK was monitored in the lysates. (B) Effect of EGF (100ng/ml for 60 min) on binding of
endogenouscapic´ ua to 14-3-3−Sepharose in lysates of PMWK melanoma cells. (C) Effect of expressing the GFP−capic´ ua constructs indicated in SKMEL13 melanoma cells. ETV1, ETV4 and ETV5
mRNA levels were quantiﬁed by qRT-PCR 24 and 48h post-transfection. All constructs encode added NLS to ensure nuclear targeting of all expressed proteins. Data were normalized to the internal
control gene B2M, and results from transfected cells are shown by black bars and untransfected cells by grey bars. (D) For the experiment shown in (C), Western blots of parallel sets of cell lysates
were performed to assess the expression levels of the proteins expressed from the constructs 48 h post-transfection. (E) Schematic diagram depicting the regulation of human capic´ ua. Activated
p90RSK phosphorylatescapic´ uaresidueseither side ofthe HMG boxcreating docking sites for a14-3-3 dimer,and thebinding of14-3-3 affects the bindingof theHMG boxto the promotersof PEA3
family transcription factors. In addition, ERK phosphorylation of Ser1409 and other sites prevents binding of importin α4/KPNA3 to the NLS of ERK1/2 capic´ ua. However, experimental disruption of
the capic´ ua−KPNA3 interaction only prevents nuclear import of the C-terminal part of capic´ u a ,a n dt h eN - t e r m i n a lp a r to fc a p i c´ ua can also enter the nucleus by another mechanism.
the therapeutic effects of ERK pathway inhibitors (such as
Gleevec) as anticancer drugs. Indeed, in the present study we
found that capic´ ua-knockdown caused signiﬁcant desensitization
of melanoma cells to the inhibitory effect of PD184352 on
ETV1 and ETV5 mRNA expression. Capic´ ua-knockdown also
enhanced cell invasion in a two-dimensional assay (Figure 2D
and Supplementary Figure S2), and how ETV1 and/or other
downstreamtargetsmediatetheeffectsofcapic´ uaonproliferation
and migration is a critical question for future research.
With these data inferring that deregulated capic´ ua could
conceivably contribute to tumour progression, we focused on the
underlying mechanistic details, and our ﬁndings are summarized
in Figure 6(E).Capic´ ua was discovered to bea target of concerted
controls by ERK itself, and via ERK-activated p90
RSK working
together with 14-3-3 proteins. The effect of ERK-mediated
phosphorylation releasing the importin-α protein KPNA3 from
theNLSintheC-terminalregionofcapic´ uaisclear,althoughhow
thisregulationhasanimpactonsubcellularlocalizationofcapic´ ua
is not. Our results indicate that the protein has at least one further
nuclear-localization mechanism mediated by the N-terminal part
of the protein, within or close to the DNA-binding HMG box.
We also found that 14-3-3 binds to p90
RSK-phosphorylated Ser
173
and a second phosphorylated residue that is possibly on the
C-terminal side of the DNA-binding HMG box, and initial results
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indicate that p90
RSK phosphorylation and 14-3-3 binding inhibits
the binding of capic´ ua to the minimal CRE (5
 -TGAATGAA-3
 )
[8]. However, it is possible that the effects of 14-3-3 on capic´ ua
maybemorecomplicatedthantheseinitialdatasuggest.Infuture,
a more thorough study of the interplay between capic´ ua, 14-3-3
and the promoter regions of each of the PEA3 transcription
factors will be required. Theevolutionary conservation of p90
RSK-
mediated binding of 14-3-3 proteins to phosphorylated Ser
173 in
human and Ser
461 in Drosophila capic´ uas respectively, suggests
that this mechanism may contribute to the relief of capic´ ua action
triggeredbyreceptortyrosinekinasesignallingduringDrosophila
development. However, no obvious matches for the NLS or other
phosphorylations in the human protein could be identiﬁed in the
Drosophila protein.
Our ﬁndings suggest that 14-3-3s should at least be considered
as potential drug targets for tumours that depend on ERK
signalling, if the drugs could be sufﬁciently well targeted to
the cancers. As well as capic´ ua, further proteins bind to 14-3-3
via p90
RSK-phosphorylated sites (S. Synowsky, O. Olsson and C.
MacKintosh, unpublished work). We also note that 14-3-3η has
been reported to contribute to prostate cancer, based on a study in
which 14-3-3η enhanced androgen- and EGF-induced androgen
receptor transcriptional activity [34]. Prototypic antagonists that
block binding of phosphorylated proteins to 14-3-3 proteins
promote apoptosis in cell-based experiments [35], which is
consistentwithindicationsthat14-3-3proteinsmaymediatemany
downstream effects of PI3K/PKB and ERK/p90
RSK signalling.
Our ﬁndings also highlight interconnections between SCA
and growth-factor signalling networks. Polyglutamine mutations
in ataxin-1 cause SCA1, and ataxin-1 protein interacts with
capic´ ua [10,15]. In this connection, it was interesting to note
that Drosophila capic´ ua contains polyglutamine stretches that
are absent in the human protein, although whether this is
coincidental or has any connection with polyglutamine disease
is obscure. It is also intriguing that capic´ ua represses the ETV1
speciﬁerofdopaminergicneurons[18],giventhatdefectsinthese
neurons underlie other movement disorders, namely Parkinson’s
disease and dopamine-responsive dystonia. Interestingly, SCA
types 14 and 27 were discovered to arise from defects in
PKCγ and the FGF14 (ﬁbroblast growth factor 14) growth
factor respectively, which have an impact on ERK signalling
[36−38]. Thus there are signs of intertwining of the molecular
networks underpinning SCAs and certain tumours. Indeed, while
the present paper was under review, ataxin-1 was reported to
interact with capic´ ua (CIC) at the promoters of genes, including
ETV5 [39]. It would be interesting to dissect further how
the gene networks effected by mutations in ataxin-1 overlap
with the gene targets of capic´ ua and ETV1, ETV4 and
ETV5. Perhaps faulty growth-factor regulation of the ataxin-1/
capic´ ua/ETV1 axis is a common denominator that interconnects
SCAs, dopaminergic disorders and cancers derived from neural
crest progenitor cells?
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ERK/p90RSK/14-3-3 signalling has an impact on expression of PEA3 Ets
transcription factors via the transcriptional repressor capic´ ua
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Figure S1 Effect of PD184352 and BI-D1870 on expression of ETV1, ETV4
and ETV5 mRNAs in Sbcl2 RAS melanoma cells
TheeffectofPD184352(2μM)andBI-D1870(10μM)onexpressionofETV1,ETV4andETV5
in Sbcl2 cells at the times indicated in hours (black bars). Gene expression is normalized to
the internal control gene B2M and is shown as the fold-expression. Levels of ETV1, ETV4 and
ETV5 mRNAs in control cells with no inhibitor are shown in grey. Values are means + − S.D.
(four different sets of analyses for each data point).
Figure S2 Effect of capic´ ua knockdown on cell migration
Cells at 30–40% conﬂuency in six-well plates were transfected with CIC siRNAs (siCIC),
non-targeting siRNA that does not target any known genes as a control (siNT) and mock
transfection. After 24h, cells were serum-deprived for 2h, detached with cell-dissociation
buffer (Gibco), counted, and added in migration buffer (750 μl of DMEM containing 1% BSA)
to the upper chambersof a growth-factor-reduced MatrigelTM invasion device (BD Biosciences)
with chemoattractant (DMEM containing 10% FCS) in the lower wells. The cells that did not
migrate were removed from the upper face of the ﬁlters using cotton swabs, and cells that had
migrated to the lower face of the ﬁlters were ﬁxed with Reastain Quick-Diff kit (Reagena) and
images(×10)werecaptured,andexamplesareshownforexperimentsinwhichchamberswere
seeded with the number of cells indicated.
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Figure S3 MS analysis of GFP–capic´ ua to identify regulated phosphorylated sites and protein–protein interactions
(A) Amino acid sequence of human capic´ ua. In lower case bold letters are the phosphorylated amino acid residues identiﬁed in the present study from MS analysis of the GFP–capic´ ua protein
from EGF-stimulated cells (SDS/PAGE in Figure 3A of the main text). The HMG box is shaded in grey and a putative NLS is in bold and underlined. (B) Positive-ion MS/MS spectrum of the
phospho-serine(pS)peptideTQ(pS)LSALPKfromatrypticdigestofhumancapic´ uafromEGF-stimulatedcells(Figure3Aofthemaintext),generatedbycollision-induceddissociationofthedoubly
charged ion of m/z = 512.840338 acquired on a Q-Trap 4000 mass spectrometer. Peptide ions derived from b-a n dy-ion fragmentation are indicated. These data pinpoint Ser173 (in grey) as the
site of phosphorylation because the 69 Da mass difference between the y7-H3PO4 ion (697.3) and the y6 ion (628.4), and also between the b3-H3PO4 ion (299.1) and b2 ion (230.1), corresponds
to the dehydroalanine generated by β-elimination of phosphoric acid from phospho-serine. In contrast, there is less evidence for phosphorylation of Thr171 and Ser175 in this phosphopeptide. amu,
atomic mass units; rel. int., relative intensity.
Figure S4 Overexpression of deletion fragments of GFP–CIC reveals additional intracellular localization mechanisms of capic´ ua in the N-terminal part of
the protein
DAPI staining and GFP immunoﬂuorescence of HEK-293 cells transfected with the indicated GFP–capic´ ua constructs. Scale bar = 10 μm.
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Figure S5 Alignment of the amino acid sequences of HMG box regions
Sequence alignment of capic´ ua from human (Homo sapiens), Drosophila, mouse (Mus musculus), rat (Rattus norvegicus), a worm (Saccoglossus kowalevskii), zebraﬁsh (Danio rerio), a beetle
(Tribolium castaneum) and a mosquito (Aedes aegypti). The arrow indicates the start of the predicted HMG box shaded in grey, and the red lower case ‘s’ indicated by the asterisk represents Ser173
in the human protein, which corresponds to Ser461 in the Drosophila capic´ ua.
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